Peter Høngaard Andersen and Jacob Hahn Michelsen join the board of Monsenso

Peter Høngaard Andersen and Jacob Hahn Michelsen join the board of Monsenso

Monsenso – a leading provider of mobile health solutions for mental health – today appointed Peter Høngaard Andersen and Jacob Hahn Michelsen to its Board of Directors.

The company’s extraordinary general meeting was held today. At the meeting, the shareholders approved the following items in accordance with the proposal stated in the notice convening the extraordinary general meeting, ref. company announcement no. 2-2021:

  1. Proposal to expand the board from 4 to 5 members.
  2. Election of members to the Board of Directors.

Thomas Knudsen resigned from the Board of Directors while Peter Høngaard Andersen and Jacob Hahn Michelsen were elected. Consequently, the Board of Directors now consists of Jukka P. Pertola (Chairman until the Annual General Meeting in 2021), Jakob E. Bardram (Deputy Chairman), Jeppe Ø. Øvlesen, Peter Høngaard Andersen and Jacob Hahn Michelsen.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Peter Høngaard Andersen and Jacob Hahn Michelsen proposed to join the board of Monsenso

Peter Høngaard Andersen and Jacob Hahn Michelsen proposed to join the board of Monsenso

Monsenso today announces that the board of Directors has decided to call for an Extraordinary General Meeting on January 29th, 2021, where two new members are proposed to be elected for the board.

Monsenso – a leading provider of mobile health solutions for mental health – plans to further strengthen the board by nominating two new professional board members with strong qualifications and competencies to support Monsenso in getting to the next level in the company’s growth journey: Peter Høngaard Andersen, formerly. Managing Director at Innovation Fund Denmark and VP at Lundbeck; Jacob Hahn Michelsen, SVP Private & Public at NNIT A/S.

Current board member Thomas Knudsen has offered to resign from his position on the board at the Extraordinary General Meeting. Thomas has supported Monsenso’s growth for several years from being a university research project spin-out to becoming an international publicly listed company on Nasdaq First North Growth Market Copenhagen. The board and the management of Monsenso would like to thank Thomas Knudsen for his outstanding work. His contributions have been essential in building up the product portfolio, securing the first rounds of financing, supporting the management and finally listing the company.

The new board is planning to constitute itself with Jukka Pertola as the Chairman and Jakob Bardram as the Vice Chairman until the next ordinary Annual General Meeting on April 14, 2021 where Jukka Pertola is expected to resign as the Chairman. Nomination of the new board members in January will help ensure an appropriate introduction, as well as a smooth transition and handover of responsibilities in the period leading up to the Annual General Meeting.

Jukka Pertola commented: ”Since I became a professional board member, I have been lucky to be invited to multiple boards of exciting companies, one of them being Monsenso. However, to address the good corporate governance requirements, I have decided to reduce my number of board positions and chairmanships. We have found an exceptionally strong pair of new board members, who can contribute to bringing Monsenso to the next level. Jacob Hahn Michelsen has extensive experience in pharma- and health-related software and IT, regulatory environment of medical applications and a valuable industry knowhow, while Peter Høngaard brings considerable experience from science and research, pharmaceuticals, neurology, intellectual property rights, innovation and funding.“

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso expands in the Middle East with new million deal with global pharmaceutical company

Monsenso has entered a new million agreement with a global pharmaceutical company and hereby expands its activities to six countries in the Middle East. As part of the agreement, Monsenso will provide its solution for patient monitoring and treatment support in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar and Bahrain.

Monsenso’s solution will be used to support the treatment of depression and schizophrenia. Patients are provided with an app, which is used to collect real-time patient-reported information and to give patients access to information about their disorder between consultations. Therapists gain access to a clinical web portal and can follow their patients remotely and gain valuable information about behavior, medication intake and symptoms and thus be able to provide a data-driven treatment and allow for proactive follow-up.
In addition, the solution supports communication between patients and therapists.

“We are very pleased with this agreement, which contributes to both expanding our geographic market coverage and our business with pharmaceutical companies in line with our growth strategy. ” says Thomas Lethenborg, CEO of Monsenso. “Depression and schizophrenia are among the most costly disorders for society and have major consequences for affected patients and relatives. Therefore, we are proud to be able to contribute to better treatment within these disease areas.”

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso is expanding in the UK with a new Sales Office and hiring of Area Sales Manager

Monsenso is expanding in the UK with a new Sales Office and hiring of Area Sales Manager

Monsenso A/S is establishing an office in the UK to support the growth plan and is hiring Michelle Woolley as Area Sales Manager.

Monsenso, a technology leader in mobile health (mHealth) solutions for mental health is opening an office in London; Monsenso UK Ltd. to strengthen and support the expansion of the business in the UK, the company has hired Michelle Woolley as Area Sales Manager.

Michelle comes to Monsenso with a strong experience in sales management and business development from both Medtech and the pharmaceutical industry from i.e. Pfizer, 3M Healthcare, Servier, and Icentia

Michelle has a Microbiology degree BSc (Hons) from University of Bristol.

Michelle Woolley starts November 9, 2020.

With the opening of an office in the UK and the hiring of Michelle, we continue Monsenso’s international expansion in line with our growth strategy. Michelle will be an important addition to the team and we look forward to welcoming her”, says CEO Thomas Lethenborg.

Click on the link to read the press release in Danish.

For additional information, please contact:

Bettina van Wylich-Muxoll
Marketing
Monsenso
+45 22 70 47 24
marketing@monsenso.com

New partership to help unemployed people get back into the labor force faster.

New partership to help unemployed people get back into the labor force faster.

New partership to help unemployed people get back into the labor force faster. Monsenso enters a partnership with Empano, a private player in psychology and psychiatry services. Together, Monsenso and Empano offer a solution for the Danish municipalities to support unemployed people suffering with stress and depression in their return to work process. Initially, the solution will be implemented in Guldborgssund Municipality, Denmark, in September 2020.

“In a situation with historically high unemployment, we are pleased to offer a solution that can help get more Danes back into the labor force faster. It’s always difficult to be outside the labor force, and even more so if you suffer from stress and depression. “Therefore, we are pleased to offer a solution to municipalities that can help unemployed people suffering with stress and depression get back to work” says CEO Thomas Lethenborg.

“The municipalities are facing a major task due to the increased unemployment we are seeing in the wake of Covid-19. The combination of our services in the psychology and psychiatry services, and Monsenso’s platform to support follow-up and data collection is unique in the market and we are convinced that the service can help municipalities to proactively help the larger group of unemployed ” says Director Camilla Stokholm Bjørkman from Empano. 

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso signs agreement to support global pharmaceutical across Europe

Monsenso signs agreement to support global pharmaceutical across Europe

Following a year-long collaboration, Monsenso signs a three-year +10 mio DKK agreement with a global pharmaceutical company.

Monsenso’s mobile health solution will be used for real-world data collection across two studies in connection with the launch of a new drug for depression treatment. The studies are expected to start in the first half of 2021 and will run over a three-year period, covering up to 2250 patients and 120 clinicians across Belgium, the Netherlands, the United Kingdom, Switzerland, Italy, Spain, Denmark, Sweden and France.

In connection with the two studies, Monsenso’s solution will be used to collect data from patients and their relatives through clinical questionnaires, daily self-assessments and behavioral data from smartphones and wearables.

In addition, the patients will be offered in-app study information and can receive reminders about medication and consultations with their clinician. Monsenso’s unique mobile health solution will in this way help increase the quality of clinical studies with real-time data collection while also facilitating better communication between patients, caregivers and clinicians.

“We are very pleased to expand our collaboration with this global pharmaceutical company and to participate in these projects. Depression is a leading burden of disease for society, and it has severe consequences for patients and their family caregivers, so we are proud to contribute to solving this problem” says Thomas Lethenborg, CEO of Monsenso. “In addition, the project will support our European expansion and our focus on partnering with pharmaceuticals, which is in line with our strategy”. 

The project will not affect Monsenso’s previously communicated plans and guidance for the 2020 financial year.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso